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Abstract 
Lentigo maligna (LM) is the in situ phase of lentigo maligna melanoma, which may 
progress to invasive melanoma if left untreated. It mainly occurs on sun-exposed areas of 
elderly patients. The lesions can be large and conventional surgery can be difficult, 
particularly on the face. Recent reports indicate that topical imiquimod 5% cream is 
effective in the treatment of LM. It may be an alternative when surgery or other classical 
treatments are not possible in elderly patients. We describe an 80-year-old Caucasian 
woman with a 10-year history of a histologically verified extensive LM of the face. She 
was treated with imiquimod 5% cream once daily. After four months it showed complete 
clinical response. One year after the treatment the patient was still free from recurrence. 
 
Introduction 
Lentigo maligna (LM), the in situ phase of lentigo maligna melanoma (LMM), may 
progress to invasive melanoma if not treated. It mainly occurs on chronically sun-exposed 
areas, typically the face, of middle-aged and elderly individuals. Surgical excision is the 
treatment of choice providing a cure in 90% of patients [1]. However this may be 
impractical or impossible due to cosmetic or functional impairment, comorbidity or 
patient preference. Nonsurgical treatments, such as cryotherapy and radiotherapy, are 
frequently used instead. More recently, imiquimod seems to be an interesting therapeutic 
alternative in the treatment of LM. 
Imiquimod is a topical immunomodulator which can generate a local cytotoxic 
response with potentially antiviral and antitumor effects. It acts through the Toll-like 
receptors 7 and 8 and activation of the transcription factor NF-kB which is followed by 
the release of various Th1 cytokines [2]. Ahmed and Berth-Jones first reported the use of 
topical imiquimod in the treatment of LM [3]. Since then many cases of success have been 
reported [1, 4–7]. A recent study comprising 48 patients with a longer described 
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follow-up period (49 months on average), showed a LM clearance rate of 79% [1]. In that 
series the response rate was lower than previously reported in the literature [4, 6]. 
Although rare, there are some cases of concern, such as an invasive melanoma that 
occurred in a patient after 1 month of imiquimod treatment [6] as well as the progression 
of LM lesions to amelanotic LMM following imiquimod therapy [8]. There are 
descriptions of a case of LM that almost cleared clinically but did not change 
histologically [9] and of the recurrence of LM 9 months after treatment [10]. 
Case Report 
An 80-year-old Caucasian woman presented with a 10-year history of an extensive pigmented lesion 
of the face. Ten years before she was referred to our department with a pigmented macule on her left 
cheek. The skin biopsy showed typical features of LM. The patient refused surgical treatment and left 
the hospital. Eight years later she returned with serious complaints. 
Physical examination revealed a brownish irregularly shaped macule, over the left hemiface, and two 
ulcerated nodules on the left cheek (fig. 1a). Dermatoscopic evaluation of the macule revealed a 
pseudo-network with asymmetrically pigmented follicular openings, rhomboidal structures and 
slate-grey pigmented areas. Excisional biopsy of the nodules was done and histopathological 
examination confirmed the evolution to melanoma with 7 mm of Breslow and Clark level IV. Three 
4-mm punch biopsies taken from different areas of the macule revealed intraepidermal proliferation of 
atypical melanocytes, epidermal atrophy and solar elastosis consistent with the diagnosis of LM. The 
patient had no adenopathy or additional lesions on physical examination. Clinical staging, including 
hematologic examination and brain, chest, abdominal and pelvic CT scan were normal. Treatment with 
imiquimod 5% cream was prescribed once daily. Four weeks later she developed an intense 
inflammatory response and the treatment was interrupted for one week (fig. 1b). After four months she 
showed complete clinical response (fig. 1c). A new 4-mm punch biopsy, three months after the 
treatment, showed no evidence of LM. One year after the treatment the patient was still free from 
recurrence. 
Discussion 
It is confirmed that imiquimod may play a role as an alternative in the management of 
LM. We found it the better choice for this elderly patient, especially given the extension of 
the lesion on the face. Furthermore she had refused the surgery and this was a palliative 
treatment. However there are several concerns about its use, particularly the lack of tissue 
for histological examination of margins, so additional studies are required. 
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Fig. 1. Extensive LM of the face. a Before treatment with imiquimod. b Cutaneous inflammation after 
1 month of treatment. c Clinical remission after 4 months of treatment. 
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